Research to develop new treatments against therapy-resistant itch is one of 23 major research projects to receive funding under a Government initiative worth €30 million over the next four to five years.
Dr Wenxin Wang is developing new synthetic biomaterials to protect against wounds forming in Epidermolysis Bullosa, or ‘butterfly skin’ disease and to help wounds heal in diabetes.
Professor Martin Steinhoff receives funding to examine potential for new biotherapeutic breakthroughs in skin disease treatment under the SFI-Pfizer Biotherapeutics Innovation Award programme
Patients with the skin condition, rosacea often experience increased skin sensitivity due to an imbalance in a layer of their skin known as the stratum corneum. Recent research findings from the Powell laboratory published in the British Journal of Dermatology show the positive impact of the drug, minocycline on skin hydration in rosacea patients.
Professor Martin Steinhoff has 20 years’ experience in the field of dermatology. In a recent article in International Innovation, he describes his expertise, research objectives and the translational nature of the work he and his team are doing on skin disease.
Three PhD positions are currently available in the 'Skin Research and Wound Healing' group led by Dr Wenxin Wang.
New research by Dr Paul Collins and colleagues in the Charles Clinic for dermatology at St. Vincent’s University Hospital could provide alternative, pain-free monitoring of patients undergoing treatment with methotrexate.
UCD Charles Institute of Dermatology is currently seeking applicants for the following professional research appointments: (1) Postdoctoral Research Fellow - Neuroimmune Communication (UCD HR Ref No. 006692); (2) Postdoctoral Research Fellow: Demodex biology and pathogenic potential (UCD HR Ref No. 006668); (3) Research Fellow - Skin Inflammation & Immunity (UCD HR Ref No. 006693); (4) Research Fellow - Skin Neurobiology & Itch (UCD HR Ref No. 006694).
Detailed job descriptions can be found on UCD website at: http://www.ucd.ie/hr/jobvacancies/ using the associated reference numbers. All applications must be submitted via the UCD online application system.
Chronic itch or pruritus is the most common symptom in dermatology yet less than 50% of patients will respond to treatment. Much like chronic pain, pruritus is detrimental to patient well-being. New research led by Professor Martin Steinhoff has identified a potential target to treat itch in patients who do not respond to anti-histamine drugs.
Dr Wenxin Wang and his team publish details of a ground-breaking synthesis process for polymers that will allow new compounds for gene therapy applications to be easily made.
As celebrations got underway around the world for St Patrick’s Festival, international experts gathered in UCD to discuss a skin disorder most commonly seen in people of Celtic origin.
UCD Charles Institute welcomes the arrival of Dr Wenxin Wang and his research group as they establish their research laboratory that will investigate how new synthetic materials can be used in the effort to treat diseases such as diabetic ulcers and Epidermolysis Bullosa (EB).
We are pleased to open registration and invite research abstracts for our 2014 Update on Rosacea symposium, to be held in the UCD Charles Institute of Dermatology, University College Dublin on Friday, 14 and Saturday, 15 March 2014.
We are pleased to invite you to our upcoming Update on Rosacea symposium, to be held in the UCD Charles Institute of Dermatology, University College Dublin on Friday 14th and Saturday 15th March 2014.
A new publication for patients suffering with rosacea is now available to download. Rosacea, The Curse of the Celts is intended as an information guide and outlines the features, causes and treatment options for the disease as well as advice on where to seek further help for the condition.
University College Dublin will lead a €1.7M European project focused on bringing novel melanoma diagnostics towards the clinic. The European Seventh Framework Programme has announced funding for a four-year international research programme, SYS-MEL, centred on new diagnostics in the melanoma arena. Melanoma is the most aggressive form of skin cancer and currently there are few effective therapies for later stages of the disease.
The BRAF mutation believed to drive disease in about half of patients with melanoma was found to occur at a significantly lower frequency in patients with melanoma in Ireland, according to data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. The study, which included two independent cohorts of patients in Europe, revealed that only about 20 percent of a cohort of Irish patients with melanoma harbored a BRAF mutation.